3.55
price up icon10.25%   0.33
 
loading
Prime Medicine Inc stock is traded at $3.55, with a volume of 3.10M. It is up +10.25% in the last 24 hours and down -21.63% over the past month. Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$3.22
Open:
$3.3
24h Volume:
3.10M
Relative Volume:
0.75
Market Cap:
$477.74M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-1.6359
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
-0.56%
1M Performance:
-21.63%
6M Performance:
+19.73%
1Y Performance:
-14.25%
1-Day Range:
Value
$3.2401
$3.64
1-Week Range:
Value
$3.0846
$3.70
52-Week Range:
Value
$1.11
$5.17

Prime Medicine Inc Stock (PRME) Company Profile

Name
Name
Prime Medicine Inc
Name
Phone
617-465-0013
Name
Address
60 FIRST ST., CAMBRIDGE
Name
Employee
214
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
PRME's Discussions on Twitter

Compare PRME with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRME
Prime Medicine Inc
3.55 623.96M 0 -217.44M -205.20M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date Action Analyst Rating Change
May-27-25 Downgrade Citigroup Buy → Neutral
May-20-25 Downgrade H.C. Wainwright Buy → Neutral
May-20-25 Downgrade JP Morgan Overweight → Neutral
Dec-10-24 Initiated JMP Securities Mkt Outperform
May-20-24 Initiated H.C. Wainwright Buy
May-16-24 Upgrade Citigroup Neutral → Buy
Apr-22-24 Initiated Chardan Capital Markets Buy
Apr-08-24 Initiated TD Cowen Buy
Apr-03-24 Initiated Wedbush Outperform
Jan-16-24 Downgrade Stifel Buy → Hold
Dec-08-23 Initiated Citigroup Neutral
Oct-09-23 Initiated BMO Capital Markets Outperform
Jul-31-23 Initiated Guggenheim Buy
Apr-18-23 Initiated Stifel Buy
Nov-14-22 Initiated Goldman Neutral
Nov-14-22 Initiated JP Morgan Overweight
Nov-14-22 Initiated Jefferies Buy
Nov-14-22 Initiated Morgan Stanley Equal-Weight
View All

Prime Medicine Inc Stock (PRME) Latest News

pulisher
Aug 20, 2025

Order Flow Trends Show Accumulation in Prime Medicine Inc.Market Trend Review & Weekly Breakout Watchlists - classian.co.kr

Aug 20, 2025
pulisher
Aug 20, 2025

Prime Medicine Insiders' Buying Signals Positive Trends - AInvest

Aug 20, 2025
pulisher
Aug 18, 2025

Prime Medicine Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 Fed Impact & Precise Swing Trade Alerts - classian.co.kr

Aug 18, 2025
pulisher
Aug 18, 2025

Reversal Confirmed Prime Medicine Inc. Stock Rallies Above MAMarket Performance Report & Community Consensus Stock Picks - classian.co.kr

Aug 18, 2025
pulisher
Aug 17, 2025

Prime Medicine announces public stock offering; shares down 11.5% - MSN

Aug 17, 2025
pulisher
Aug 16, 2025

How Prime Medicine Inc. stock performs during market volatilityMarket Movers & Daily Momentum Trading Reports - sundaytimes.kr

Aug 16, 2025
pulisher
Aug 14, 2025

Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid promising tech - Investing.com

Aug 14, 2025
pulisher
Aug 14, 2025

RSI Suggests Rebound May Be Near in Prime Medicine Inc.Bond Market & Expert Approved Momentum Ideas - beatles.ru

Aug 14, 2025
pulisher
Aug 14, 2025

Prime Medicine, Inc. shares rise 2.10% premarket after positive market sentiment. - AInvest

Aug 14, 2025
pulisher
Aug 13, 2025

Prime Medicine (PRME.O) Sees Sharp Intraday Surge—What’s Behind the Move? - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Guggenheim cuts Prime Medicine stock price target to $5 from $18 - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Does Prime Medicine Inc. stock reflect fundamentalsJuly 2025 Earnings & Expert Curated Trade Ideas - thegnnews.com

Aug 13, 2025
pulisher
Aug 12, 2025

Is Prime Medicine Inc. exposed to political riskUltra High Profit Potential - newsyoung.net

Aug 12, 2025
pulisher
Aug 12, 2025

Prime Healthcare Services Receives Universal Credit Rating Upgrades from Fitch, Moody's and S&P - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Is Prime Medicine Inc. forming higher highs and higher lowsMulti-Bagger Picks in Progress - thegnnews.com

Aug 12, 2025
pulisher
Aug 11, 2025

H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating - 富途牛牛

Aug 11, 2025
pulisher
Aug 10, 2025

Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00 - Defense World

Aug 10, 2025
pulisher
Aug 10, 2025

What makes Prime Medicine Inc. stock price move sharplyHigh Return Trade Roadmap with Setup Filters - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Prime Medicine Inc. stock trendline breakdownFree Consistent Income Focused Trade List - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

How high can Prime Medicine Inc. stock goFree Community Verified Stock Suggestions - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

Prime Medicine stock price target lowered to $10 at Chardan on cash update - Investing.com Canada

Aug 08, 2025
pulisher
Aug 08, 2025

Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Prime Medicine Inc. stock retracement – recovery analysisFree Stock Market Entry Timing Signals - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Prime Medicine Reports Q2 2025 Results and Strategic Updates - TipRanks

Aug 08, 2025
pulisher
Aug 07, 2025

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

PRME Revenue Misses by 73% - AOL.com

Aug 07, 2025
pulisher
Aug 07, 2025

Prime Medicine reports Q2 EPS (41c), consensus (34c) - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Prime Medicine, Inc. SEC 10-Q Report - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Prime Medicine, Inc. Q2 operating expenses USD 54.492 million - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Alphabet Discloses $4.95 Million Equity Purchase in Prime Medicine via GV - TechGraph

Aug 07, 2025
pulisher
Aug 06, 2025

Major Investment Alert: Prime Medicine, Inc. Sees Significant Share Purchase! - TipRanks

Aug 06, 2025
pulisher
Aug 06, 2025

Prime Medicine (NYSE:PRME) Shares Gap Up Following Insider Buying Activity - Defense World

Aug 06, 2025
pulisher
Aug 06, 2025

Why Prime Medicine Inc. stock attracts strong analyst attentionPrice Action Summary and Entry Strategy Guide - Newser

Aug 06, 2025
pulisher
Aug 05, 2025

Prime Medicine Holds Special Stockholder Meeting - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Bank of New York Mellon Corp Acquires 26,478 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World

Aug 05, 2025
pulisher
Aug 05, 2025

Head to Head Comparison: Prime Medicine (NYSE:PRME) vs. Calidi Biotherapeutics (NYSE:CLDI) - Defense World

Aug 05, 2025
pulisher
Aug 05, 2025

Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity - Defense World

Aug 05, 2025
pulisher
Aug 04, 2025

Firm Advises Prime Medicine on IP Matters Related to $144 Million Public Offering - Wilson Sonsini

Aug 04, 2025
pulisher
Aug 04, 2025

Prime Medicine Surges 8.5% Amid KDJ Golden Cross Signal and Biotech Sector Rally - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Prime Medicine (PRME.O) Sees Sharp Intraday Surge—What’s Driving the Move? - AInvest

Aug 04, 2025
pulisher
Aug 03, 2025

Why is Prime Medicine Inc. stock attracting strong analyst attentionAchieve rapid capital gains with smart investing - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Prime Medicine Inc.Free Consultation - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Prime Medicine Inc. stockGet insider insights into market trends - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What drives Prime Medicine Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Prime Medicine Inc. company’s key revenue driversAchieve breakthrough performance in the market - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Prime Medicine Inc. stock expected to show significant growthUnlock your portfolio’s hidden potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Prime Medicine Inc. stockStay informed with daily expert analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

Is Prime Medicine Inc. a growth stock or a value stockInvest confidently with advanced analysis tools - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What is the risk reward ratio of investing in Prime Medicine Inc. stockUnlock powerful market trend analysis - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Is Prime Medicine Inc. stock overvalued or undervaluedInvest smarter with daily market updates - Jammu Links News

Aug 02, 2025

Prime Medicine Inc Stock (PRME) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Prime Medicine Inc Stock (PRME) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
NELSEN ROBERT
Director
Aug 01 '25
Buy
3.30
3,030,300
9,999,990
6,230,300
ARCH Venture Partners XII, LLC
10% Owner
Aug 01 '25
Buy
3.30
3,030,300
9,999,990
6,230,300
ARCH Venture Partners X, LLC
10% Owner
Aug 01 '25
Buy
3.30
3,030,300
9,999,990
6,230,300
Liu David R.
10% Owner
Jun 30 '25
Buy
2.52
21,000
52,830
20,240,945
Liu David R.
10% Owner
Jun 23 '25
Buy
2.16
21,000
45,402
20,219,945
Liu David R.
10% Owner
Jun 16 '25
Buy
1.49
21,000
31,196
20,198,945
Liu David R.
10% Owner
Jun 11 '25
Buy
1.60
21,000
33,590
20,177,945
Brudnick Richard
Chief Business Officer
May 20 '25
Buy
1.19
20,000
23,790
20,000
LEE ANN L.
Chief Technical Officer
May 21 '25
Buy
1.13
100,000
113,000
100,000
Reine Allan
Chief Executive Officer
May 21 '25
Buy
1.18
125,000
147,150
125,000
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):